Top Markets
#1 ADO Protocol ADO Protocol +328.50%
#2 GoPlus Security GoPlus Security +54.02%
#3 Starpower Starpower +38.38%
#4 Verus Coin Verus Coin +33.62%
#5 Tutorial Tutorial +32.38%
#6 Nockchain Nockchain +32.34%
#7 Chainflip Chainflip +28.46%
#8 The Black Bull The Black Bull +26.41%
#9 GAIB AID GAIB AID +24.67%
#10 peaq peaq +17.79%
Coin of the day
ADO Protocol ADO Protocol
Setări
Limbă
ROMâNă
Monedă
USD
Temă
NuCana plc NuCana plc

NuCana plc

NCNA
Rang în acțiuni #32773
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering... NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Preț acțiune
$1.51
Capitalizare de piață
$9.14M
Schimbare (1 zi)
-5.35%
Schimbare (1 an)
-59.65%
Țară
GB
Tranzacționează NuCana plc (NCNA)

Categorie

Healthcare
Câștiguri pentru NuCana plc (NCNA)
Câștiguri în 2026 TTM: 0
Conform celor mai recente rapoarte financiare ale NuCana plc, câștigurile actuale ale companiei sunt 0. În anul 2026, compania a înregistrat un câștig de 0, egal cu câștigului din 2026, care a fost de 0. Câștigurile afișate pe această pagină sunt cele înainte de dobânzi și impozite, cunoscute și ca EBIT.
Istoricul câștigurilor pentru NuCana plc din 2026 până în 2026
Câștiguri la sfârșitul fiecărui an
An Câștiguri Schimbă
Nu sunt suficiente date pentru perioada selectată.
Câștiguri pentru companii similare sau concurente
Companie Câștiguri Diferență de câștiguri Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE